News & Updates
Showing Cardiology articles
Showing
Solo ticagrelor after 1-month DAPT: Is it time to change practice?
Dropping aspirin for ticagrelor monotherapy 1 month after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is as good as dual antiplatelet therapy (DAPT) in the ULTIMATE-DAPT* trial presented at ACC.24.
GLP-1 RA plus SGLT-2i better than monotherapy for CV, renal events prevention
Patients with type 2 diabetes (T2D) who received combined treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a much lower risk of major adverse cardiovascular events (MACE) and serious renal events than those treated with either drug class alone, suggests a recent study.
Semaglutide benefits extend to HFpEF patients with T2D
The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.
Prognosis role of blood urea nitrogen to serum albumin ratio established in IPAH
A higher ratio of blood urea nitrogen to serum albumin is indicative of worse outcomes and disease severity in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a study.
